Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Cell Death & Disease|February 16, 2021
Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancerNing Zhang, Yu-Nan Tian, Li-Na Zhou, et al.Journal of Medicinal Chemistry|March 12, 2013
Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitorsNa Ye, Chuan-Huizi Chen, Tiantian Chen, et al.Oncotarget|April 4, 2015
Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibitionJun-Mei Yi, Xiao-Fei Zhang, Xia-Juan Huan, et al.Investigational New Drugs|July 4, 2019
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis inductionMohammadali Soleimani Damaneh, Jian-Ping Hu, Xia-Juan Huan, et al.Ecotoxicology and Environmental Safety|July 9, 2021
High incidence of multi-drug resistance and heterogeneity of mobile genetic elements in Escherichia coli isolates from diseased ducks in Sichuan province of ChinaShaqiu Zhang, Shuling Chen, Muhammad Abbas, et al.Ecotoxicology and Environmental Safety|May 28, 2021
Distribution and association of antimicrobial resistance and virulence traits in Escherichia coli isolates from healthy waterfowls in Hainan, ChinaShaqiu Zhang, Shuling Chen, Mujeeb Ur Rehman, et al.Acta Tropica|March 12, 2019
High prevalence of CTX-M belonging to ST410 and ST889 among ESBL producing E. coli isolates from waterfowl birds in China's tropical island, HainanHong Yang, Mujeeb Ur Rehman, Shaqiu Zhang, et al.Journal of Medicinal Chemistry|September 7, 2019
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein InhibitorsJianping Hu, Chang-Qing Tian, Mohammadali Soleimani Damaneh, et al.EMBO Molecular Medicine|January 18, 2023
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceLi-Min Wang, Pingyuan Wang, Xiao-Min Chen, et al.Cancer Letters|November 17, 2016
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trialsBo Yuan, Na Ye, Shan-Shan Song, et al.Pageof 6